Yahoo
Canadian Sec - Free Realtime Quote CAD

Pharmala Biotech Holdings Inc. (MDMA.CN)

0.1750 +0.0050 (+2.94%)
As of 11:02:23 AM EST. Market Open.
Chart Range Bar
Loading chart for MDMA.CN
  • Previous Close 0.1700
  • Open 0.1800
  • Bid 0.1750 x --
  • Ask 0.1900 x --
  • Day's Range 0.1750 - 0.1800
  • 52 Week Range 0.0850 - 0.3300
  • Volume 4,000
  • Avg. Volume 193,858
  • Market Cap (intraday) 19.281M
  • Beta (5Y Monthly) 0.87
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.

pharmala.ca

--

Full Time Employees

August 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

MDMA.CN
59.09%
S&P/TSX Composite index (^GSPTSE)
12.83%

1-Year Return

MDMA.CN
40.00%
S&P/TSX Composite index (^GSPTSE)
18.81%

3-Year Return

MDMA.CN
34.62%
S&P/TSX Composite index (^GSPTSE)
83.19%

5-Year Return

MDMA.CN
60.23%
S&P/TSX Composite index (^GSPTSE)
69.83%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -126.87%

  • Return on Assets (ttm)

    -26.50%

  • Return on Equity (ttm)

    -68.66%

  • Revenue (ttm)

    1.27M

  • Net Income Avi to Common (ttm)

    -1.61M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    249.14k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -398.14k

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: